99 related articles for article (PubMed ID: 38569555)
1. EDA2R-NIK signaling in cancer cachexia.
Agca S; Kir S
Curr Opin Support Palliat Care; 2024 May; ():. PubMed ID: 38801457
[TBL] [Abstract][Full Text] [Related]
2. The role of extracellular vesicles in skeletal muscle wasting.
Zhang X; Zhao Y; Yan W
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2462-2472. PubMed ID: 37867162
[TBL] [Abstract][Full Text] [Related]
3. Adverse effects of systemic cancer therapy on skeletal muscle: myotoxicity comes out of the closet.
Klassen P; Schiessel DL; Baracos VE
Curr Opin Clin Nutr Metab Care; 2023 May; 26(3):210-218. PubMed ID: 36942895
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M: Dual Regulator of the Skeletal and Hematopoietic Systems.
Sims NA; Lévesque JP
Curr Osteoporos Rep; 2024 Feb; 22(1):80-95. PubMed ID: 38198032
[TBL] [Abstract][Full Text] [Related]
5. Oncostatin M signaling drives cancer-associated skeletal muscle wasting.
Domaniku-Waraich A; Agca S; Toledo B; Sucuoglu M; Özen SD; Bilgic SN; Arabaci DH; Kashgari AE; Kir S
Cell Rep Med; 2024 Apr; 5(4):101498. PubMed ID: 38569555
[TBL] [Abstract][Full Text] [Related]
6. Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis.
Jengelley DHA; Wang M; Narasimhan A; Rupert JE; Young AR; Zhong X; Horan DJ; Robling AG; Koniaris LG; Zimmers TA
Cytokine; 2022 Nov; 159():155972. PubMed ID: 36054964
[TBL] [Abstract][Full Text] [Related]
7. A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.
Seto DN; Kandarian SC; Jackman RW
J Biol Chem; 2015 Aug; 290(32):19976-86. PubMed ID: 26092726
[TBL] [Abstract][Full Text] [Related]
8. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation.
Miki Y; Morioka T; Shioi A; Fujimoto K; Sakura T; Uedono H; Kakutani Y; Ochi A; Mori K; Shoji T; Emoto M; Inaba M
Biochem Biophys Res Commun; 2019 Aug; 516(3):951-956. PubMed ID: 31272716
[TBL] [Abstract][Full Text] [Related]
10. Muscle wasting: emerging pathways and potential drug targets.
Domaniku A; Bilgic SN; Kir S
Trends Pharmacol Sci; 2023 Oct; 44(10):705-718. PubMed ID: 37596181
[TBL] [Abstract][Full Text] [Related]
11. EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia.
Bilgic SN; Domaniku A; Toledo B; Agca S; Weber BZC; Arabaci DH; Ozornek Z; Lause P; Thissen JP; Loumaye A; Kir S
Nature; 2023 May; 617(7962):827-834. PubMed ID: 37165186
[TBL] [Abstract][Full Text] [Related]
12. Cachexia: A systemic consequence of progressive, unresolved disease.
Ferrer M; Anthony TG; Ayres JS; Biffi G; Brown JC; Caan BJ; Cespedes Feliciano EM; Coll AP; Dunne RF; Goncalves MD; Grethlein J; Heymsfield SB; Hui S; Jamal-Hanjani M; Lam JM; Lewis DY; McCandlish D; Mustian KM; O'Rahilly S; Perrimon N; White EP; Janowitz T
Cell; 2023 Apr; 186(9):1824-1845. PubMed ID: 37116469
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management.
Argilés JM; López-Soriano FJ; Stemmler B; Busquets S
Nat Rev Clin Oncol; 2023 Apr; 20(4):250-264. PubMed ID: 36806788
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
